Research Topics
Species | Michael R McClungSummaryAffiliation: Oregon Osteoporosis Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
BisphosphonatesMichael McClung
Oregon Osteoporosis Center, Portland, OR 97213, USA
Arq Bras Endocrinol Metabol 50:735-44. 2006..Potent bisphosphonates are generally the preferred treatment option for most patients with or at risk for osteoporosis...
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosisMichael R McClung
Oregon Osteoporosis Center, Portland, OR, USA
J Bone Miner Res 27:211-8. 2012..The effect of denosumab on nonvertebral fracture risk differed by femoral neck BMD, BMI, and prevalent vertebral fracture at baseline. © 2012 American Society for Bone and Mineral Research...
A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year dataMichael R McClung
Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 626, Portland, OR 97213, USA
Calcif Tissue Int 92:59-67. 2013..This monthly regimen may provide a more convenient dosing schedule to some patients with postmenopausal osteoporosis...- Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 yearsM R McClung
Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, Portland, OR 97213, USA
Osteoporos Int 24:301-10. 2013..Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance... - Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trialM R McClung
Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 626, Portland, OR 97213, USA
Osteoporos Int 24:227-35. 2013..Denosumab treatment was well tolerated throughout the 8-year study... - Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year dataM R McClung
Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, Portland, OR 97213, USA
Osteoporos Int 24:293-9. 2013..This adds to the range of risedronate dosing options and provides an alternative for patients who prefer once-a-month dosing... - Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holidayMichael McClung
Oregon Osteoporosis Center, Portland, OR 97213, USA
Am J Med 126:13-20. 2013.... - Denosumab in postmenopausal women with low bone mineral densityMichael R McClung
Providence Portland Medical Center, Portland, Oreg, USA
N Engl J Med 354:821-31. 2006..The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action... - Do current management strategies and guidelines adequately address fracture risk?Michael R McClung
Department of Medical Education, Providence Portland Medical Center, Portland, OR 97213, USA
Bone 38:S13-7. 2006..Revised treatment guidelines, based upon thresholds of absolute fracture risk, will provide the opportunity to identify and to treat those women who will most benefit from our therapies... - Opposite bone remodeling effects of teriparatide and alendronate in increasing bone massMichael R McClung
Oregon Osteoporosis Center, Providence Portland Medical Center, Portland, OR 97213, USA
Arch Intern Med 165:1762-8. 2005..We contrasted the effects of once-daily doses of 20 mug of teriparatide and 10 mg of alendronate sodium on bone mineral density (BMD) and markers of bone turnover... - The relationship between bone mineral density and fracture riskMichael R McClung
Oregon Osteoporosis Center, 5050 Northeast Hoyt Street, Suite 651, Portland, OR 97213, USA
Curr Osteoporos Rep 3:57-63. 2005..By basing who to treat on fracture probability, therapy can be targeted to those patients who would receive the greatest benefit... - Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studiesMichael R McClung
Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 651, Portland, OR 97210, USA
Curr Osteoporos Rep 4:28-33. 2006..These results provide the basis for studies evaluating the effectiveness of denosumab in several clinical conditions characterized by increased osteoclastic activity... - Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifeneMichael R McClung
Oregon Osteoporosis Center, Portland, OR 97213, USA
Menopause 13:377-86. 2006..The objective of this study was to compare the effects of lasofoxifene with raloxifene and placebo on indices of bone health in postmenopausal women... - Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronateMichael McClung
Oregon Osteoporosis Center, 5050 NE, Hoyt Street, Ste 651, Portland, OR 97213 2954, USA
Bone 41:122-8. 2007..We conclude that patients can be switched from oral ALN to ZOL 5 mg infusion with maintenance of therapeutic effect for at least 12 months and that patients prefer a once yearly infusion to weekly oral therapy... 
Role of RANKL inhibition in osteoporosisMichael McClung
Oregon Osteoporosis Center, Portland, Oregon 97213, USA
Arthritis Res Ther 9:S3. 2007..More information about the effectiveness of denosumab in reducing fracture risk, its tolerability and safety, and the response to discontinuing therapy will be provided by ongoing clinical studies...- The clinical and epidemiologic consequences of redefining treatment criteria: who should be treated?Michael McClung
Oregon Osteoporosis Center, Portland, Oregon 97213, USA
Salud Publica Mex 51:S46-51. 2009..It is expected that, with these algorithms, the cost and effectiveness of medical care for patients with osteoporosis will be improved... - Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trialMichael McClung
Oregon Osteoporosis Center, Portland, Oregon, USA
Obstet Gynecol 114:999-1007. 2009..To evaluate the efficacy of zoledronic acid in the prevention of bone loss in postmenopausal women with low bone mass... - Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tabletM R McClung
Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, Portland, OR 97213, USA
Osteoporos Int 23:267-76. 2012..Delayed-release risedronate is a convenient regimen for oral bisphosphonate therapy... - Use of highly potent bisphosphonates in the treatment of osteoporosisMichael McClung
Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 651, Portland, OR 97213, USA
Curr Osteoporos Rep 1:116-22. 2003..Potent bisphosphonates are now the preferred treatment option to reduce the fracture risk in men and women with involutional and glucocorticoid-induced osteoporosis... - Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone lossMichael R McClung
Oregon Osteoporosis Center, Portland, OR 97213, USA
Bone 44:418-22. 2009..The objective of this study was to examine the efficacy and safety of monthly oral ibandronate (150 mg) treatment in postmenopausal women with low bone mass... - BisphosphonatesMichael R McClung
Department of Medical Education, Providence Portland Medical Center and the Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 651, Portland, Oregon 97213, USA
Endocrinol Metab Clin North Am 32:253-71. 2003..Having these effective agents challenges clinicians to identify the most appropriate patients for bisphosphonate use and to develop strategies to improve acceptance of and adherence to these useful agents... - Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort StudyMichael R McClung
Oregon Osteoporosis Center, 5050 Northeast Hoyt, Suite 651, Portland, Oregon 97213, USA
J Clin Endocrinol Metab 89:4879-85. 2004..5, 10.3, and 8.9% of women taking placebo, 2.5 mg alendronate, or 5 mg alendronate daily, respectively. Therapy with alendronate is an effective and promising strategy for the prevention of postmenopausal osteoporosis... - Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosisMichael R McClung
Oregon Osteoporosis Center, Portland, Oregon 97213, USA
J Bone Miner Res 19:11-8. 2004..1% and 1.8%, respectively; p < or = 0.0001 versus placebo) with 2.5 mg ibandronate after 24 months. Oral ibandronate is a promising option for the prevention of postmenopausal bone loss... - Parathyroid hormone for the treatment of osteoporosisMichael McClung
Oregon Osteoporosis Center, Department of Medical Education, Providence Portland Medical Center, Portland, Oregon, USA
Obstet Gynecol Surv 59:826-32. 2004.... - The menopause and HRT. Prevention and management of osteoporosisMichael R McClung
Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 651, Portland, OR 97210, USA
Best Pract Res Clin Endocrinol Metab 17:53-71. 2003..Reducing both the frequency and the effects of falls complements the efforts of treating osteoporosis to reduce the incidence of fractures and their important clinical consequences... - A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral densityEric Orwoll
Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA
J Clin Endocrinol Metab 97:3161-9. 2012..Men with low bone mineral density (BMD) were treated with denosumab... - Pathogenesis of osteoporotic hip fracturesMichael R McClung
Oregon Osteoporosis Center, Portland, Oregon, USA
Clin Cornerstone . 2003..For elderly patients, the use of hip protectors may be used as a treatment of last resort. Regardless of the age of the patient, individual patient risk factors must be considered to target appropriate treatment and prevent fracture... - Osteoporosis in men: epidemiology, diagnosis, prevention, and treatmentWojciech P Olszynski
Department of Medicine, University of Saskatchewan, Saskatoon Osteoporosis Centre, Saskatoon, Saskatchewan, Canada
Clin Ther 26:15-28. 2004..Osteoporosis and fragility fractures in men account for substantial health care expenditures and decreased quality of life... - Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fracturesEthel S Siris
Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
J Clin Endocrinol Metab 88:3482-6. 2003..A call to action is necessary to reduce the human and economic costs associated with this serious and treatable disease... - A national random survey of bone mineral density reporting in the United StatesGhada El-Hajj Fuleihan
Calcium Metabolism and Osteoporosis Program, American University of Beirut Medical Center, Beirut, Lebanon
J Clin Densitom 5:3-9. 2002..A re-examination of the practice of clinical densitometry reporting is warranted... - How does raloxifene reduce fracture risk?Michael R McClung
Menopause 9:306-8. 2002 - Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort studyMichael Steinbuch
Procter and Gamble Pharmaceuticals, Mason, Ohio, USA
Regul Toxicol Pharmacol 35:320-6. 2002..Follow-up mortality data in this retrospective cohort study demonstrate that treatment with risedronate has no effect on overall mortality rates... - Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trialSusan L Greenspan
University of Pittsburgh Osteoporosis Prevention and Treatment Center, 1110 Kaufmann Building, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA
Ann Intern Med 136:742-6. 2002..001). CONCLUSION: Alendronate increased BMD at both the spine and hip in elderly female residents of long-term care facilities... - Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trialPaul D Miller
Colorado Center for Bone Research, 3190 South Wadsworth Blvd, Ste 250, Lakewood, CO 80227, USA
Bone 43:222-9. 2008..We assessed the long-term efficacy and safety of denosumab, and the effects of discontinuing and restarting denosumab treatment in postmenopausal women with low bone mass... - Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisPierre D Delmas
INSERM Research Unit 831 and University of Lyon, Lyon, France
Bone 42:36-42. 2008..This randomized, double-blind, multi-center study was designed to assess the efficacy and safety of a single 150 mg risedronate once-a-month oral dose compared with the 5 mg daily regimen... - Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trialHenry G Bone
Michigan Bone and Mineral Clinic, 22201 Moross Road, Suite 260, Detroit, Michigan 48236 2175, USA
J Clin Endocrinol Metab 92:4671-7. 2007..Observational studies and secondary analyses from lipid-lowering trials have yielded inconsistent results regarding the effect of these agents on bone mineral density and fracture risk... - Osteopenia: to treat or not to treat?Michael R McClung
Ann Intern Med 142:796-7. 2005 - Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its useAnthony B Hodsman
University of Western Ontario, St Joseph s Health Care, Room 2F 15, 268, Grosvenor Street, London, Ontario N6A 4V2, Canada
Endocr Rev 26:688-703. 2005..At present, concurrent therapy with antiresorptive therapy, particularly bisphosphonates, should be avoided, although sequential therapy with such agents may consolidate the beneficial effects upon the skeleton after PTH is discontinued... - Changes in bone density and turnover after alendronate or estrogen withdrawalRichard D Wasnich
Radiant Research Honolulu, Honolulu, HI 96814, USA
Menopause 11:622-30. 2004..To compare bone mineral density (BMD) and bone turnover changes after therapy withdrawal in postmenopausal women treated with alendronate or estrogen-progestin... - Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest oldSteven Boonen
Leuven University Center for Metabolic Bone Diseases and Division of Geriatric Medicine, Katholieke Universiteit Leuven, Herestraat 49, B-3000 Leuven, Belgium
J Am Geriatr Soc 52:1832-9. 2004..Because each therapeutic agent used for the treatment of osteoporosis may have unique characteristics, the observations made in this study should not be assumed to apply to other bisphosphonates... - Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuationAndrew M Kaunitz
Department of Obstetrics and Gynecology, University of Florida Health Science Center, Jacksonville, FL 32209, USA
Contraception 74:90-9. 2006..This 7-year, prospective, matched-cohort, clinical study evaluated the effects of intramuscular depot medroxyprogesterone acetate (DMPA) (150 mg/mL) on bone mineral density (BMD) in women aged 25-35 years... - Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE studyPaul D Miller
Colorado Center for Bone Research, Lakewood, Colorado, USA
J Bone Miner Res 20:1315-22. 2005..5 mg; 3-year vertebral fracture risk reduction: 52%) oral ibandronate regimens were compared in 1609 women with postmenopausal osteoporosis. At least equivalent efficacy and similar safety and tolerability were shown after 1 year... - Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMDE Michael Lewiecki
New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106, USA
J Bone Miner Res 22:1832-41. 2007..Continued study of denosumab is warranted in the treatment of low BMD in postmenopausal women... - A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronateJean Yves Reginster
Unite d Exploration du Metabolisme de l Os et du Cartilage, CHU Centre Ville, Liege, Belgium
Osteoporos Int 17:159-66. 2006..Greater convenience and tolerability may enhance the therapy adherence and, hence, improve long-term therapeutic outcomes in PMO... - Bisphosphonates and osteonecrosis of the jawNelson B Watts
Ann Intern Med 145:791-2; author reply 792. 2006 - Looking for answers in all the wrong placesMichael R McClung
Menopause 14:7-9. 2007 - Official positions of the international society for clinical densitometryE Michael Lewiecki
New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico 87106, USA
J Clin Endocrinol Metab 89:3651-5. 2004..Recommendations that are accepted become the Official Positions of the ISCD. This Special Report summarizes the methodology of the ISCD Position Development Conferences and presents selected Official Positions of general interest...